Abstract
| Original language | English |
|---|---|
| Journal | European Journal of Neurology |
| DOIs | |
| Publication status | Published - Dec 8 2019 |
Fingerprint
Cite this
Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. / Gastaldi, M; Mariotto, S; Giannoccaro, M P; Iorio, R; Zoccarato, M; Nosadini, M; Benedetti, L; Casagrande, S; Di Filippo, M; Valeriani, M; Ricci, S; Bova, S; Arbasino, C; Mauri, M; Versino, M; Vigevano, F; Papetti, L; Romoli, M; Lapucci, C; Massa, F; Sartori, S; Zuliani, L; Barilaro, A; De Gaspari, P; Spagni, G; Evoli, A; Liguori, R; Ferrari, S; Marchioni, E; Giometto, B; Massacesi, L; Franciotta, D.
In: European Journal of Neurology, 08.12.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study
AU - Gastaldi, M
AU - Mariotto, S
AU - Giannoccaro, M P
AU - Iorio, R
AU - Zoccarato, M
AU - Nosadini, M
AU - Benedetti, L
AU - Casagrande, S
AU - Di Filippo, M
AU - Valeriani, M
AU - Ricci, S
AU - Bova, S
AU - Arbasino, C
AU - Mauri, M
AU - Versino, M
AU - Vigevano, F
AU - Papetti, L
AU - Romoli, M
AU - Lapucci, C
AU - Massa, F
AU - Sartori, S
AU - Zuliani, L
AU - Barilaro, A
AU - De Gaspari, P
AU - Spagni, G
AU - Evoli, A
AU - Liguori, R
AU - Ferrari, S
AU - Marchioni, E
AU - Giometto, B
AU - Massacesi, L
AU - Franciotta, D
N1 - © 2019 EAN.
PY - 2019/12/8
Y1 - 2019/12/8
N2 - BACKGROUND: Autoimmune encephalitides (AE) include a spectrum of neurological disorders, whose diagnosis revolves around the detection of neuronal antibodies (Abs). Consensus-based diagnostic criteria (AE-DC) allow clinic-serological subgrouping of AE, with unclear prognostic implications. We studied AE-DC impact on patients' management, focusing on the subgroup of Ab-negative-AE.METHODS: Retrospective multicenter study on patients fulfilling AE-DC. All patients underwent Ab testing with commercial cell-based-assays (CBAs) and, when available, in-house assays (immunohistochemistry, live/fixed CBAs, neuronal cultures), that contributed to define final categories. Patients were classified as Ab-positive-AE [NMDAR-encephalitis (NMDAR-E), Ab-positive limbic encephalitis (LE), definite-AE], or Ab-negative-AE (Ab-negative-LE, probable-AE, possible-AE).RESULTS: Commercial CBAs detected neuronal Abs in 70/118(59.3%) patients. Testing 37/48 Ab-negative cases, in-house assays identified Abs in 11 patients (29.7%). One-hundred-eighteen patients fulfilled AE-DC, 81(68.6%) with Ab-positive-AE (Ab-positive-LE, 40; NMDAR-E, 32; definite-AE, 9), 37(31.4%) with Ab-negative-AE (Ab-negative-LE, 17; probable/possible-AE, 20). Clinical phenotypes were similar in Ab-positive- vs Ab-negative-LE. Twenty-four/118(20.3%) patients had tumors, and 19/118(16.1%) relapsed, regardless of being Ab-positive or Ab-negative. Ab-positive-AE patients were treated earlier than Ab-negative-AE patients (p=0.045), responded more frequently to treatments (92.3% vs 65.6%, p
AB - BACKGROUND: Autoimmune encephalitides (AE) include a spectrum of neurological disorders, whose diagnosis revolves around the detection of neuronal antibodies (Abs). Consensus-based diagnostic criteria (AE-DC) allow clinic-serological subgrouping of AE, with unclear prognostic implications. We studied AE-DC impact on patients' management, focusing on the subgroup of Ab-negative-AE.METHODS: Retrospective multicenter study on patients fulfilling AE-DC. All patients underwent Ab testing with commercial cell-based-assays (CBAs) and, when available, in-house assays (immunohistochemistry, live/fixed CBAs, neuronal cultures), that contributed to define final categories. Patients were classified as Ab-positive-AE [NMDAR-encephalitis (NMDAR-E), Ab-positive limbic encephalitis (LE), definite-AE], or Ab-negative-AE (Ab-negative-LE, probable-AE, possible-AE).RESULTS: Commercial CBAs detected neuronal Abs in 70/118(59.3%) patients. Testing 37/48 Ab-negative cases, in-house assays identified Abs in 11 patients (29.7%). One-hundred-eighteen patients fulfilled AE-DC, 81(68.6%) with Ab-positive-AE (Ab-positive-LE, 40; NMDAR-E, 32; definite-AE, 9), 37(31.4%) with Ab-negative-AE (Ab-negative-LE, 17; probable/possible-AE, 20). Clinical phenotypes were similar in Ab-positive- vs Ab-negative-LE. Twenty-four/118(20.3%) patients had tumors, and 19/118(16.1%) relapsed, regardless of being Ab-positive or Ab-negative. Ab-positive-AE patients were treated earlier than Ab-negative-AE patients (p=0.045), responded more frequently to treatments (92.3% vs 65.6%, p
U2 - 10.1111/ene.14139
DO - 10.1111/ene.14139
M3 - Article
JO - European Journal of Neurology
JF - European Journal of Neurology
SN - 1351-5101
ER -